Literature DB >> 11867820

Macrolide antibiotics and cystic fibrosis.

D G Peckham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11867820      PMCID： PMC1746280          DOI： 10.1136/thorax.57.3.189

Source DB:  PubMed          Journal:  Thorax        ISSN： 0040-6376            Impact factor:   9.139


× No keyword cloud information.
  4 in total

1.  Management of refractory Pseudomonas aeruginosa infection in cystic fibrosis.

Authors:  Roger Sordé; Albert Pahissa; Jordi Rello
Journal:  Infect Drug Resist       Date:  2011-01-25       Impact factor: 4.003

Review 2.  Measuring and reporting quality of life outcomes in clinical trials in cystic fibrosis: a critical review.

Authors:  Janice Abbott; Anna Hart
Journal:  Health Qual Life Outcomes       Date:  2005-03-24       Impact factor: 3.186

3.  Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lung.

Authors:  Leopoldo N Segal; Jose C Clemente; Benjamin G Wu; William R Wikoff; Zhan Gao; Yonghua Li; Jane P Ko; William N Rom; Martin J Blaser; Michael D Weiden
Journal:  Thorax       Date:  2016-08-02       Impact factor: 9.139

4.  Effects of long-term macrolide therapy at low doses in stable COPD.

Authors:  Yueqin Cao; Shurui Xuan; Yunhui Wu; Xin Yao
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-06-12
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.